Genfit (GNFT) Competitors

Genfit (NASDAQ:GNFT) and Nuvation Bio (NYSE:NUVB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, community ranking, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.

Which has more volatility & risk, GNFT or NUVB?

Genfit has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500. Comparatively, Nuvation Bio has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500.

Which has preferable valuation and earnings, GNFT or NUVB?

Genfit has higher revenue and earnings than Nuvation Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genfit	$76.06M	2.29	-$31.27M	N/A	N/A
Nuvation Bio	$7.87M	84.53	-$75.80M	-$2.26	-0.87

Is GNFT or NUVB more profitable?

Genfit's return on equity of 0.00% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genfit	N/A	N/A	N/A
Nuvation Bio	N/A	-21.89%	-17.86%

Does the MarketBeat Community believe in GNFT or NUVB?

Genfit received 15 more outperform votes than Nuvation Bio when rated by MarketBeat users. However, 81.82% of users gave Nuvation Bio an outperform vote while only 69.70% of users gave Genfit an outperform vote.

Company	Underperform	Outperform
Genfit	Outperform Votes 69 69.70%	Underperform Votes 30 30.30%
Nuvation Bio	Outperform Votes 54 81.82%	Underperform Votes 12 18.18%

Does the media prefer GNFT or NUVB?

In the previous week, Nuvation Bio had 3 more articles in the media than Genfit. MarketBeat recorded 5 mentions for Nuvation Bio and 2 mentions for Genfit. Nuvation Bio's average media sentiment score of 1.38 beat Genfit's score of 0.00 indicating that Nuvation Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genfit	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nuvation Bio	3 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders & institutionals have more ownership in GNFT or NUVB?

2.2% of Genfit shares are held by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are held by institutional investors. 4.2% of Genfit shares are held by company insiders. Comparatively, 5.1% of Nuvation Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Do analysts rate GNFT or NUVB?

Genfit currently has a consensus target price of $13.00, suggesting a potential upside of 273.03%. Nuvation Bio has a consensus target price of $8.75, suggesting a potential upside of 345.29%. Given Nuvation Bio's stronger consensus rating and higher possible upside, analysts clearly believe Nuvation Bio is more favorable than Genfit.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genfit	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Nuvation Bio	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25

Summary

Nuvation Bio beats Genfit on 11 of the 16 factors compared between the two stocks.